Federated Hermes, Inc. Vaxart, Inc. Transaction History

Federated Hermes, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.6 - $1.41 $3,054 - $7,176	-5,090 Reduced 66.06%	2,615 $1,000
Q1 2023 May 08, 2023	BUY	$0.71 - $1.25 $3,482 - $6,131	4,905 Added 175.18%	7,705 $5,000
Q4 2022 Feb 13, 2023	BUY	$0.75 - $2.24 $2,100 - $6,272	2,800 New	2,800 $2,000
Q2 2022 Aug 15, 2022	BUY	$2.7 - $5.28 $2 - $5	1 New	1 $1,000
Q4 2020 Feb 12, 2021	SELL	$3.5 - $7.98 $581 - $1,324	-166 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$4.78 - $16.97 $38 - $135	-8 Reduced 4.6%	166 $1,000
Q2 2020 Aug 13, 2020	BUY	$1.68 - $8.85 $292 - $1,539	174 New	174 $1,000

110

37.6M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $73.4M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.